Mannkind (MNKD) Interest Coverage Ratio (2010 - 2026)
Mannkind (MNKD) reported Interest Coverage Ratio of 0.22 for Q1 2026, down 104.64% year-over-year from 4.8 in Q1 2025, and up 78.15% on a QoQ basis from 1.02 in Q4 2025.
Mannkind (MNKD) has 17 years of Interest Coverage Ratio data on file, last reported at 0.22 in Q1 2026.
- Quarterly Interest Coverage Ratio fell 104.64% year-over-year to 0.22 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.89 (down 83.98% YoY) and the FY2025 annual result came in at 2.81, down 53.69% from the prior year.
- Interest Coverage Ratio grew to 0.22 in Q1 2026 per MNKD's latest filing, from 1.02 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 18.59 in Q2 2025 and bottomed at 7.74 in Q1 2022.
- The 5-year median for Interest Coverage Ratio is 1.81 (2023), against an average of 3.14.
- The widest annual swing landed in 2022, when Interest Coverage Ratio slumped 706.12%; it then surged 996.25% in 2024.
- Tracing MNKD's Interest Coverage Ratio over 5 years: stood at 4.55 in 2022, then jumped by 164.47% to 2.94 in 2023, then jumped by 477.86% to 16.96 in 2024, then tumbled by 106.01% to 1.02 in 2025, then surged by 78.15% to 0.22 in 2026.
- Per Business Quant, the three latest MNKD Interest Coverage Ratio figures stand at 0.22 (Q1 2026), 1.02 (Q4 2025), and 13.85 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -129.79 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3.58 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -258.33 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 11.50 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 49.84 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 3.88 |
| 10 | Mannkind | 1.09 Bn | 956.66 Mn | 82.66 Mn | -0.22 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.22 |
| Dec 31, 2025 | -1.02 |
| Sep 30, 2025 | 13.85 |
| Jun 30, 2025 | 18.59 |
| Mar 31, 2025 | 4.80 |
| Dec 31, 2024 | 16.96 |
| Sep 30, 2024 | 7.08 |
| Jun 30, 2024 | 2.75 |
| Mar 31, 2024 | 6.51 |
| Dec 31, 2023 | 2.94 |
| Sep 30, 2023 | 1.81 |
| Jun 30, 2023 | 0.25 |
| Mar 31, 2023 | -2.15 |
| Dec 31, 2022 | -4.55 |
| Sep 30, 2022 | -3.42 |
| Jun 30, 2022 | -3.08 |
| Mar 31, 2022 | -7.74 |
| Dec 31, 2021 | -8.66 |
| Sep 30, 2021 | -2.35 |
| Jun 30, 2021 | -3.23 |
| Mar 31, 2021 | -0.96 |
| Dec 31, 2020 | -3.79 |
| Sep 30, 2020 | -8.64 |
| Jun 30, 2020 | -7.30 |
| Mar 31, 2020 | -6.65 |
| Dec 31, 2019 | -11.12 |
| Sep 30, 2019 | -2.13 |
| Jun 30, 2019 | -19.42 |
| Mar 31, 2019 | -22.79 |
| Dec 31, 2018 | -12.47 |
| Sep 30, 2018 | -21.69 |
| Jun 30, 2018 | -12.02 |
| Mar 31, 2018 | -14.93 |
| Dec 31, 2017 | -14.03 |
| Sep 30, 2017 | -12.20 |
| Jun 30, 2017 | -13.04 |
| Mar 31, 2017 | -7.24 |
| Dec 31, 2016 | -3.93 |
| Sep 30, 2016 | 28.38 |
| Jun 30, 2016 | -4.57 |
| Mar 31, 2016 | -4.74 |
| Dec 31, 2015 | -81.89 |
| Sep 30, 2015 | -6.27 |
| Jun 30, 2015 | -5.82 |
| Mar 31, 2015 | -3.75 |
| Dec 31, 2014 | -5.32 |
| Sep 30, 2014 | -7.05 |
| Jun 30, 2014 | -28.76 |
| Mar 31, 2014 | -10.25 |
| Dec 31, 2013 | -4.07 |
| Sep 30, 2013 | -10.35 |
| Jun 30, 2013 | -14.51 |
| Mar 31, 2013 | -12.73 |
| Dec 31, 2012 | -2.51 |
| Sep 30, 2012 | -12.41 |
| Jun 30, 2012 | -15.49 |
| Mar 31, 2012 | -13.18 |
| Dec 31, 2011 | -10.73 |
| Sep 30, 2011 | -11.52 |
| Jun 30, 2011 | -13.83 |
| Mar 31, 2011 | -15.75 |
| Dec 31, 2010 | -11.34 |
| Sep 30, 2010 | -22.68 |
| Jun 30, 2010 | -30.77 |